Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice

Journal of Pathology

Volumn 233, Issue 2, 2014, Pages 148-158

  Foth, Mona ^a,b   Ahmad, Imran ^b   Van Rhijn, Bas W G ^c   Van Der Kwast, Theodorus ^d   Bergman, Andre M ^d   King, Louise ^a   Ridgway, Rachel ^b   Leung, Hing Y ^b   Fraser, Sioban ^e   Sansom, Owen J ^b   Iwata, Tomoko ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

comparative pathology; fibroblast growth factors; personalized therapy; prognostic marker; transgenic mouse model; transitional cell carcinoma

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL ENLARGEMENT; CELL PROLIFERATION; CELL VACUOLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; THICKNESS; TISSUE MICROARRAY; URINARY TRACT CANCER;

COMPARATIVE PATHOLOGY; FIBROBLAST GROWTH FACTORS; PERSONALIZED THERAPY; PROGNOSTIC MARKER; TRANSGENIC MOUSE MODEL; TRANSITIONAL CELL CARCINOMA;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SIZE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84900833911     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4334     Document Type: Article

References (49)

1. Stenzl A, Cowan NC, De Santis M, et al., The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-825.
2. Zieger K, Dyrskjot L, Wiuf C, et al., Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005; 11: 7709-7719.
3. Herr HW,. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000; 163: 60-61; discussion 61-62.
4. Knowles MA,. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008; 13: 287-297.
5. Billerey C, Chopin D, Aubriot-Lorton MH, et al., Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158: 1955-1959.
6. Jebar AH, Hurst CD, Tomlinson DC, et al., FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24: 5218-5225.
7. Lamy A, Gobet F, Laurent M, et al., Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006; 176: 2686-2689.
8. Lindgren D, Liedberg F, Andersson A, et al., Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006; 25: 2685-2696.
9. Tomlinson DC, Blado O, Hamden P, et al., FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213: 91-98.
10. Goetz R, Mohammadi M,. Exploring mechanisms of FGF signalling through the lens of structural biology. Nature Rev Mol Cell Biol 2013; 14: 166-180.
11. Laederich MB, Horton WA,. FGFR3 targeting strategies for achondroplasia. Expert Rev Mol Med 2012; 14: e11.
12. Iwata T, Chen L, Li C, et al., A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum Mol Genet 2000; 9: 1603-1613.
13. Iwata T, Li CL, Deng CX, et al., Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. Hum Mol Genet 2001; 10: 1255-1264.
14. Iwata T, Hevner RF,. Fibroblast growth factor signaling in development of the cerebral cortex. Dev Growth Differ 2009; 51: 299-323.
15. Ahmad I, Iwata T, Leung HY,. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 2012; 1823: 850-860.
16. Chesi M., Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729-736.
17. Logie A., Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005; 14: 1153-1160.
18. Qing J, Du X, Chen Y, et al., Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009; 119: 1216-1229.
19. Ahmad I, Singh LB, Foth M, et al., K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech 2011; 4: 548-555.
20. Lopez-Knowles E, Hernandez S, Malats N, et al., PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006; 66: 7401-7404.
21. Platt FM, Hurst CD, Taylor CF, et al., Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009; 15: 6008-6017.
22. Kompier LC, Lurkin I, van der Aa MN, et al., FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010; 5: e13821.
23. Juanpere N, Agell L, Lorenzo M, et al., Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum Pathol 2012; 43: 1573-1582.
24. Duenas M, Martinez-Fernandez M, Garcia-Escudero R, et al., PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog 2013 (Epub ahead of print); DOI: 10.1002/mc.22125.
25. Calderaro J, Rebouissou S, de Koning L, et al., PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer 2013 (Epub ahead of print); DOI: 10.1002/ijc.28518.
26. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, et al., Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010; 28: 401-408.
27. Tsuruta H., Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006; 66: 8389-8396.
28. Yoo LI, Liu DW, Le Vu S, et al., Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res 2006; 66: 1929-1939.
29. Mo L, Cheng J, Lee EY, et al., Gene deletion in urothelium by specific expression of Cre recombinase. Am J Physiol Renal Physiol 2005; 289: F562-F568.
30. Lesche R, Groszer M, Gao J, et al., Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002; 32: 148-149.
31. Novak A, Guo C, Yang W, et al., Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 2000; 28: 147-155.
32. Dupuy AJ, Rogers LM, Kim J, et al., A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 2009; 69: 8150-8156.
33. Zhang ZT, Pak J, Shapiro E, et al., Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999; 59: 3512-3517.
34. Ahmad I, Morton JP, Singh LB, et al., β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 2011; 30: 178-189.
35. Kong XT,. Roles of uroplakins in plaque formation, umbrella cell enlargement, and urinary tract diseases. J Cell Biol 2004; 167: 1195-1204.
36. Shin K, Lee J, Guo N, et al., Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 2011; 472: 110-114.
37. Yohn NL, Bingaman CN, DuMont AL, et al., Phosphatidylinositol 3'-kinase, mTOR, and glycogen synthase kinase-3β mediated regulation of p21 in human urothelial carcinoma cells. BMC Urol 2011; 11: 19.
38. Askham JM, Platt F, Chambers PA, et al., AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010; 29: 150-155.
39. Korkolopoulou P, Levidou G, Trigka EA, et al., A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int 2012; 110: E1237-E1248.
40. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al., Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23: 675-680.
41. van Rhijn BW, Montironi R, Zwarthoff EC, et al., Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198: 245-251.
42. Ross RL, Askham JM, Knowles MA,. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene 2013; 32: 768-776.
43. Cho JY, Guo C, Torello M, et al., Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci U S A 2004; 101: 609-614.
44. Brooks AN, Kilgour E, Smith PD,. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18: 1855-1862.
45. Lamont FR, Tomlinson DC, Cooper PA, et al., Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104: 75-82.
46. Guagnano V, Furet P, Spanka C, et al., Discovery of 3-(2,6-dichloro-3,5- dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54: 7066-7083.
47. Gavine PR, Mooney L, Kilgour E, et al., AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72: 2045-2056.
48. Sjodahl G, Lauss M, Lovgren K, et al., A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012; 18: 3377-3386.
49. Tomlinson DC, Lamont FR, Shnyder SD, et al., Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009; 69: 4613-4620.